Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy
暂无分享,去创建一个
H. Brodt | B. Kamps | P. Gute | Bernhard Knupp | S. Staszewski | E. Helm | H. Brodt | E. Helm
[1] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[2] Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.
[3] J. Kahn,et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. , 1989, JAMA.
[4] Incidence of Kaposi's sarcoma in a cohort of homosexual men infected with the human immunodeficiency virus type 1. The Multicenter AIDS Cohort Study Group. , 1990, Journal of acquired immune deficiency syndromes.
[5] S. Steinberg,et al. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. , 1990, Annals of internal medicine.
[6] G. Rutherford,et al. Kaposi's sarcoma among homosexual and bisexual men enrolled in the San Francisco City Clinic Cohort Study. , 1990, Journal of Acquired Immune Deficiency Syndromes.
[7] J. Phair,et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS , 1991, The Lancet.
[8] B. Saltzman,et al. Survival differences in patients with AIDS. , 1991, Journal of acquired immune deficiency syndromes.
[9] Opportunistic non-Hodgkin's lymphomas among severely immunocompromised HIV-infected patients surviving for prolonged periods on antiretroviral therapy--United States. , 1991, MMWR. Morbidity and mortality weekly report.
[10] J. Carlin,et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. , 1991, Journal of acquired immune deficiency syndromes.
[11] S. Broder,et al. The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] T Creagh-Kirk,et al. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, AIDS.
[13] M. Lederman,et al. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. , 1992, JAMA.
[14] O. Hamouda,et al. Changes in the Spectrum of AIDS‐Defining Conditions and Decrease in CD4+ Lymphocyte Counts at AIDS Manifestation in Germany from 1986 to 1991 , 1992, AIDS.
[15] P M Southern,et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. , 1992, The Journal of infectious diseases.
[16] J. Phair,et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. , 1993, The New England journal of medicine.
[17] Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men. , 1993, Journal of acquired immune deficiency syndromes.
[18] J. Chmiel,et al. Composite risk score for Kaposi's sarcoma based on a case-control and longitudinal study in the Multicenter AIDS Cohort Study (MACS) population. , 1993, American journal of epidemiology.
[19] C. Rabkin. Epidemiology of AIDS‐related malignancies , 1994, Current opinion in oncology.
[20] J. Phair,et al. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study. , 1994, The Journal of infectious diseases.
[21] M. Moroni,et al. Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study. , 1994, The American journal of gastroenterology.
[22] S. Buchbinder,et al. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. , 1994, The Journal of infectious diseases.
[23] C. Katlama,et al. HIV‐related non‐Hodgkin's lymphoma among European AIDS patients , 1995, European journal of haematology.
[24] B. Nathwani,et al. Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma. , 1995, Blood.
[25] Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 x 10(6)/l. , 1995, AIDS.
[26] J. Neaton,et al. Frequencies of opportunistic diseases prior to death among HIV‐infected persons , 1995, AIDS.
[27] J. Phair,et al. Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 x 10(6)/l. , 1995, AIDS.
[28] D. Hoover. The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature. , 1995, Drugs.
[29] J. Nielsen,et al. Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. , 1995, Scandinavian journal of infectious diseases.
[30] P. Rosenberg,et al. Changing patterns of Kaposi's sarcoma in Danish acquired immunodeficiency syndrome patients with complete follow-up. The Danish Study Group for HIV Infection (DASHI). , 1995, American journal of epidemiology.
[31] A. Tosteson,et al. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS , 1996, AIDS.
[32] S. Hammer,et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.
[33] J. Meynard,et al. Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposi's sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion. , 1996, The Journal of infectious diseases.
[34] J. Ward,et al. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends , 1996, AIDS.
[35] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[36] S. Mallal,et al. Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort , 1996, AIDS.
[37] S. Hammer,et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.
[38] V. Johnson,et al. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals , 1997, AIDS.
[39] P. Kvale,et al. Incidence of Tuberculosis in the United States among HIV-Infected Persons , 1997, Annals of Internal Medicine.
[40] Impact of disseminated Mycobacterium avium-complex infection on survival of HIV-infected patients. , 1997, European journal of medical research.
[41] C. Katlama,et al. Reductions in HIV‐1 disease progression for zidovudine/lamivudine relative to control treatments: a meta‐analysis of controlled trials , 1997, AIDS.